# US 2013/0280289 A1 · Mycobacterium antigenic composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280289 A1
- Document ID: US20130280289A1
- Status: Published application
- Kind: A1
- Application number: 13/993,386
- Filed: 2011-12-14
- Published: 2013-10-24
- Earliest claimed: 2010-12-14
- Assignees: Glaxosmithkline Biologicals SA
- Inventors: Stéphane André Georges Godart; Amina Laanan; Dominique Ingrid Lemoine
- Web page: https://patentgrep.com/patent/US20130280289A1

## CPC

- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.

## Claims

### Claim 1

An immunogenic composition comprising an M72 related antigen, wherein:
(i) the conductivity of the composition is 13 mS/cm or lower; and/or
(ii) the concentration of salts in said composition is 130 mM or lower; and/or
(iii) the concentration of sodium chloride in said composition is 130 mM or lower.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The immunogenic composition according to claim 1, wherein the conductivity of the composition is 3 mS/cm or lower.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The immunogenic composition according to claim 1, wherein the concentration of salts in said composition is 40 mM or lower.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The immunogenic composition according to claim 1, wherein the concentration of sodium chloride in said composition is 40 mM or lower.

### Claim at position 8

8-10. (canceled)

### Claim 11 (depends on 1)

The immunogenic composition according to claim 1, further comprising a non-ionic tonicity agent.

### Claim 12 (depends on 5)

The immunogenic composition according to claim 5, wherein the non-ionic tonicity agent is a polyol.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The immunogenic composition according to claim 12, wherein the polyol is sorbitol and wherein the concentration of sorbitol is between about 4 and about 6% (w/v).

### Claim 15 (depends on 1)

The immunogenic composition according to claim 1, wherein the concentration of sucrose is between about 4 and about 6% (w/v).

### Claim 16 (depends on 1)

The immunogenic composition according to claim 1, further comprising one or more immuno stimulants.

### Claim at position 15

17-18. (canceled)

### Claim 19 (depends on 16)

The immunogenic composition according to claim 16, wherein the immunogenic composition comprises QS21.

### Claim 20 (depends on 16)

The immunogenic composition according to claim 16, wherein the immunogenic composition comprises 3-de-O-acylated monophoshoryl lipid A.

### Claim 21 (depends on 1)

The immunogenic composition according to claim 1, wherein the osmolality is 250 to 750 mOsm/kg.

### Claim at position 19

22-24. (canceled)

### Claim 25 (depends on 1)

The immunogenic composition according to claim 1, wherein the composition is provided as a unit dose of between 50 ul and 1 ml and wherein the unit dose contains 5 to 50 ug of M72 related protein.

### Claim 26 (depends on 1)

The immunogenic composition according to claim 1, wherein the pH of said composition is in the range 7.0 to 9.0.

### Claim at position 22

27-31. (canceled)

### Claim 32 (depends on 1)

The immunogenic composition according to claim 1, wherein the M72 related antigen comprises the amino acid sequence of SEQ ID No: 3.

### Claim 33

(canceled)

### Claim 34 (depends on 32)

The immunogenic composition according to claim 32, wherein the M72 related antigen consists of the amino acid sequence of SEQ ID No: 3.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

A pharmaceutical composition comprising the immunogenic composition according to claim 1.

### Claim 37

(canceled)

### Claim 38 (depends on 31)

A method for the prophylaxis, treatment or amelioration of infection by mycobacteria, such as infection by Mycobacterium tuberculosis, comprising the administration of a safe and effective amount of an immunogenic composition according to claim 31.

### Claim 39 (depends on 31)

A process for the making an immunogenic composition according to claim 31, comprising the steps:
a) lyophilising an M72 related antigen; and
b) reconstituting the lyophilised M72 related antigen of step a) with an aqueous solution wherein:
(i) the conductivity of the solution is 13 mS/cm or lower; and/or
(ii) the concentration of salts in said solution is 130 mM or lower; and/or
(iii) the concentration of sodium chloride in said solution is 130 mM or lower.

### Claim 40 (depends on 31)

A method for the manufacture of a stable immunogenic composition according to claim 31, comprising the steps:
a) lyophilising an M72 related antigen; and
b) reconstituting the lyophilised M72 related antigen of step a) with an aqueous solution wherein:
(i) the conductivity of the solution is 13 mS/cm or lower; and/or
(ii) the concentration of salts in said solution is 130 mM or lower; and/or
(iii) the concentration of sodium chloride in said solution is 130 mM or lower;
wherein at least 80% of the antigenicity of the immunogenic composition remains after storage at 25° C. for a period of 24 hours.

### Claim 41

A kit comprising:
a) a lyophilised M72 related antigen; and
b) an aqueous solution wherein:
(i) the conductivity of the solution is 13 mS/cm or lower; and/or
(ii) the concentration of salts in said solution is 130 mM or lower; and/or
(iii) the concentration of sodium chloride in said solution is 130 mM or lower.

### Claim at position 33

42-47. (canceled)
